Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2004-10-06
2010-10-05
Ewoldt, G. R (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007240, C424S001570, C424S009340, C424S450000
Reexamination Certificate
active
07807377
ABSTRACT:
The present invention concerns artificial antigen presenting cells (aAPCs) and methods of making and using the same, for example, to isolate, identify, and expand T cell populations specifically reactive against a disease-associated antigenic peptide, as well as to modulate responses of antigen-specific T cells both in vivo, ex vivo, and in vitro. Accordingly, the aAPCs of the invention can be used to treat conditions that would benefit from modulation of a T cell response, for example, autoimmune disorders, allergies, cancers, viral infections, and graft rejection. In certain preferred embodiments, the aAPCs are liposomes comprised of MHC:peptide complexes and accessory molecules. Other molecules, such as co-stimulatory molecules and adhesion molecules, can also be included in the compositions of the invention. In other embodiments, the aAPCs are comprised of a scaffold to which a plurality of MHC:peptide complexes and accessory molecules (as well as other molecules) can be attached at high density.
REFERENCES:
patent: 4400376 (1983-08-01), Sanderson
patent: 4478823 (1984-10-01), Sanderson
patent: 4690915 (1987-09-01), Rosenberg
patent: 4885172 (1989-12-01), Bally et al.
patent: 5194253 (1993-03-01), Garrido
patent: 5216132 (1993-06-01), Basi
patent: 5283058 (1994-02-01), Faustman
patent: 5468481 (1995-11-01), Sharma et al.
patent: 5595881 (1997-01-01), Kendrick et al.
patent: 5623056 (1997-04-01), Tykocinski et al.
patent: 5635363 (1997-06-01), Altman et al.
patent: 5693522 (1997-12-01), Chada et al.
patent: 5734023 (1998-03-01), Nag et al.
patent: 5750356 (1998-05-01), Spack et al.
patent: 5756666 (1998-05-01), Takiguchi et al.
patent: 5763585 (1998-06-01), Nag
patent: 5773570 (1998-06-01), Carson et al.
patent: 5776487 (1998-07-01), Wilson et al.
patent: 5780319 (1998-07-01), Maxfield Wilson et al.
patent: 5788963 (1998-08-01), Murphy et al.
patent: 5827516 (1998-10-01), Urban et al.
patent: 5834015 (1998-11-01), Oleske et al.
patent: 5861290 (1999-01-01), Goldsmith et al.
patent: 5876721 (1999-03-01), Alexander et al.
patent: 5880103 (1999-03-01), Urban et al.
patent: 5891689 (1999-04-01), Takle et al.
patent: 6576428 (2003-06-01), Assenmacher et al.
patent: 97/46256 (1997-11-01), None
Janeway and Travers. ImmunoBiology. 1994. 7:9-10.
Oertli, D., et al. Cin. Exp. Immunol. 1997; 110:144-149.
Walden, “Antigen presentation by liposomes,”Hamatologie Und Bluttransfusion29:481-5 (1985).
Walden et al., “Induction of regulatory T-lymphocyte responses by liposomes carrying major histocompatibility complex molecules and foreign antigen,”Nature315(6017):327-329 (1985).
Albani et al, “Positive selection in autoimmunity: Abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis,”Nat. Med. 1:448-452 (1995).
Albani et al., “A multistep molecular mimicry hypothesis for the pathogenesis of rheumatoid arthritis,”Immunology Today17:466-470 (1996).
Albani et al., “Diagnostic value of a lymphocyte stimulation test in cow milk protein intolerance,”Annals of Allergy63(12):489-192 (1989).
Alexander et al., “Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides,”Immunity1:751-761 (1994).
Altman et al. “Phenotypic analysis of antigen-specific T lymphocytes,”Science274:94-96 (1996).
Anderson et al., “Weak peptide agonists reveal functional differences in B7-1 and B7-2 costimulation of human T cell clones,”J. Immunol. 159(4):1669-1675 (1997).
Arimilli et al., “Refolding and reconstitution of functionally active complexes of human leukocyte antigen DR2 and myelin basic protein peptide from recombinant α and β polypeptide chains,” Journal of Biological Chemistry 270(2):971-977 (1995).
Bachmann et al., “Distinct roles for LFA-1 and CD28 during activation of naïve T cells: Adhesion versus costimulation,”Immunity7:549-557 (1997).
Barnado et al., “Allele-specific HLA-B*15 typing by PCR-SSP and its application to four distinct ethnic populations,”Tissue Antigens51(3):293-300 (1998).
Blotta et al., “Cross-linking of the CD40 ligand on human CD4+ T lymphocytes generates a costimulatory signal that up-regulates IL-4 synthesis,”J. Immunol. 156:3133-3140 (1996).
Bona et al., “Towards development of T-cell vaccines,” Immunology Today (Mar. 1998).
Bonnin et al., “Mucosal modulation of immune responses to heat shock proteins in autoimmune arthritis,” Biotherapy 10:213-221 (1998).
Bonnin et al., “Ontogemy of synonymous T cell populations with specificity for a self-MHC epitope mimicked by a bacterial homologue: an antigen specific T cell analysis in a non-transgenic system,”Eur. J. Immunol. (In press) (1999).
Brian et al., “Allogeneic stimulation of cytotoxic T cells by supported planar membranes,” Proc. Natl. Acad. Sci. 61:6159-6163 (1984).
Buus et al., “Isolation and characterization of antigen-la complexes involved in T cell recognition,” Cell 47:1071-1077 (1986).
Carlsson et al., “Protein thiolation and reversible protein-protein conjugation,” Biochem. J. 173:723-737 (1978).
Clark et al., “Antigen-specific deletion of cloned T cells using peptide-toxin conjugate complexed with purified class II major histocompatibility complex antigen,” Journal of Biological Chemistry 269(1):94-99 (1994).
Crawford et al., “Detection of antigen specific T cells with multivalent soluble class II MHC covalent peptide complexes,” Immunity 8:675-682 (1998).
Demotz, “DR αβ dimers released from complexes with invariant chain fail to stimulate alloreactive T cell clones,” Eur. J. Immunology 23:2100-2108 (1993).
Demotz, “The ligands of the class II major histocompatibility complex-restricted T cells,” Chem. Immunol. 57:18-38 (1993).
Ding et al., “Activation of CD4+T cells by delivery of the B7 costimulatory signal on bystander antigen-presenting cells (trans-costimutation),”European Journal of Immunology24(4):859-868 (1994).
Dubey et al., “Naïve and effector CD4 T cells differ in their requirements for T cell receptor versus costimulatory signals,”J. Immunol. 157:3820-3289 (1996).
Eberl et al., “A simple mathematical model for the functional peptide/MHC/TCR interactions,” Journal of Immunology 154:219-225 (1995).
Finger et al., “Adhesion through L-selectin requires a threshold hydrodynamic shear,”Nature379:268-269 (1996).
Flynn, “CD4 T cell cytokine differentiation: The B cell activation molecule, OX40 ligand, Instructs CD4 T cells to express interleukin 4 and upregutates expression of the chemokine receptor, Blr-1,”Journal of Experimental Medicine168(2):297-304 (1998).
Frumento et al., “Cellular mechanisms of artificial peptides binding to HLA, International Journal of Artificial Organs,” 14:518-522 (1991).
Garboczi et al., “Structure of the complex between human T-cell receptor, viral peptide and HLA-A2,”Nature384:134-141 (1996).
Garcia et al., “Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen,”Science279:1166-1172 (1998).
Gaur et al, “Amelioration of relapsing experimental autoimmune enoephalomyetitis with altered myelin basic protein peptides Involves different cellular mechanisms,”J. of Neuroimmunol. 74:149-158 (1997).
Gay et al., “The major histocompatibility complex-restricted antigen receptor on T cells,”Journal of Immunology136(6):2026-2032 (1986).
Gimmi et al., “Human T-cell clonal energy is induced by antigen presentation in the absence of B7 costimulation,” Proc. Natl. Acad. Sci. 90:6586-6590 (1993).
Grakoul et al., “The immunological synapse: A molecular machine controlling T cell activation,” Science 285:221-227 (1999).
Greten et al., “Direct visualizat
Albani Salvatore
BioTechnology Law Group
Chambers Daniel M.
Ewoldt G. R
Murdock Douglas C.
LandOfFree
Method of isolating antigen-specific T cells employing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of isolating antigen-specific T cells employing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of isolating antigen-specific T cells employing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4173916